801 reports of this reaction
3.3% of all VALGANCICLOVIR HYDROCHLORIDE POWDER, reports
#4 most reported adverse reaction
NEUTROPENIA is the #4 most commonly reported adverse reaction for VALGANCICLOVIR HYDROCHLORIDE POWDER,, manufactured by Ajanta Pharma USA Inc.. There are 801 FDA adverse event reports linking VALGANCICLOVIR HYDROCHLORIDE POWDER, to NEUTROPENIA. This represents approximately 3.3% of all 24,571 adverse event reports for this drug.
Patients taking VALGANCICLOVIR HYDROCHLORIDE POWDER, who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among VALGANCICLOVIR HYDROCHLORIDE POWDER, users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for VALGANCICLOVIR HYDROCHLORIDE POWDER,:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 801 FDA reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.3% of all adverse event reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,, making it a notable side effect.
If you experience neutropenia while taking VALGANCICLOVIR HYDROCHLORIDE POWDER,, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.